Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles.
amastigotes
gold nanoparticles
promastigotes
surface plasmon resonance
visceral leishmaniasis L. donovani
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
11
2020
accepted:
15
09
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
25
11
2021
Statut:
epublish
Résumé
The current therapeutic armory for visceral leishmaniasis (VL) caused by GNP were synthesized and characterized for particle size by dynamic light scattering (DLS) and atomic force microscopy (AFM) and for optical properties by UV-visible spectroscopy. Cytotoxicity of GNP was measured by the MTT proliferation assay. The antileishmanial activity of the nanoparticles was evaluated against GNP showed a strong SPR peak at 520 nm and mean particle size, polydispersity index (PDI), and zeta potential of 56.0 ± 10 nm, 0.3 ± 0.1 and -27.0 ± 3 mV, respectively. The GNPs were smooth and spherical with a mean particle diameter of 20 ± 5 nm. Nanoparticles [1.2-100 µM] did not reveal any cytotoxicity on RAW 264.7 murine macrophage cell line, but exerted significant activity against both promastigotes and amastigote stages of GNP may provide a platform to conjugate antileishmanial drugs onto the surface of nanoparticles to enhance their therapeutic effectiveness against VL. Further work is warranted, involving more in-depth mechanistic studies and in vivo investigations.
Identifiants
pubmed: 34737566
doi: 10.2147/IJN.S268548
pii: 268548
pmc: PMC8560327
doi:
Substances chimiques
Antiprotozoal Agents
0
Pharmaceutical Preparations
0
Gold
7440-57-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7285-7295Informations de copyright
© 2021 Want et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Am J Trop Med Hyg. 2020 Jul;103(1):308-314
pubmed: 32394874
Colloids Surf B Biointerfaces. 2015 May 1;129:107-13
pubmed: 25835145
ChemMedChem. 2013 Oct;8(10):1634-7
pubmed: 24039168
Sci Rep. 2021 Jan 21;11(1):1974
pubmed: 33479338
Appl Biochem Biotechnol. 2012 Nov;168(6):1549-55
pubmed: 23054815
Int J Hyperthermia. 2013;29(1):79-86
pubmed: 23311381
Amino Acids. 2012 Feb;42(2-3):803-11
pubmed: 21833767
PLoS Negl Trop Dis. 2011 Jul;5(7):e1253
pubmed: 21811648
Acta Trop. 2018 Feb;178:46-54
pubmed: 29111137
Front Pharmacol. 2020 Aug 14;11:1246
pubmed: 32922290
Int J Biol Macromol. 2018 Feb;107(Pt A):212-221
pubmed: 28867228
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S86-S94
pubmed: 30033773
PLoS Negl Trop Dis. 2018 Jul 12;12(7):e0006639
pubmed: 30001317
J Nanobiotechnology. 2012 May 06;10:19
pubmed: 22559747
Parasit Vectors. 2015 Mar 26;8:183
pubmed: 25884649
J Food Prot. 2012 Apr;75(4):701-5
pubmed: 22488058
Biomaterials. 2012 Mar;33(7):2327-33
pubmed: 22182745
BMC Infect Dis. 2020 Jan 6;20(1):10
pubmed: 31906924
Int J Nanomedicine. 2019 Aug 20;14:6073-6101
pubmed: 31686803
Nanomedicine (Lond). 2011 Sep;6(7):1175-88
pubmed: 21675859
Bioact Mater. 2021 May 08;6(12):4470-4490
pubmed: 34027235
Methods. 2006 Sep;40(1):1-9
pubmed: 16997708
J Colloid Interface Sci. 2014 Oct 15;432:258-69
pubmed: 25086720
J Family Med Prim Care. 2020 Mar 26;9(3):1362-1369
pubmed: 32509616
J Nanosci Nanotechnol. 2021 Feb 1;21(2):1266-1271
pubmed: 33183471
Molecules. 2017 Aug 31;22(9):
pubmed: 28858253
Int J Nanomedicine. 2017 Jul 26;12:5289-5311
pubmed: 28794624
World J Microbiol Biotechnol. 2018 Feb 19;34(3):38
pubmed: 29460068
Chem Biol Interact. 2020 Apr 1;320:109026
pubmed: 32112863
Int J Pharm. 2018 Aug 25;547(1-2):421-431
pubmed: 29886097
ACS Med Chem Lett. 2010 Dec 29;2(3):230-3
pubmed: 24900299
PLoS One. 2013 Dec 10;8(12):e81492
pubmed: 24339938
Drug Deliv Transl Res. 2021 Feb;11(1):118-130
pubmed: 32016707
Int J Nanomedicine. 2019 Feb 25;14:1469-1487
pubmed: 30880959
J Parasit Dis. 2016 Sep;40(3):935-9
pubmed: 27605813
Antimicrob Agents Chemother. 2013 Jul;57(7):2913-22
pubmed: 23571538
Nanotoxicology. 2011 Sep;5(3):284-95
pubmed: 20849214
Pharmacol Res. 2019 Jan;139:375-383
pubmed: 30503838
Talanta. 2011 Feb 15;83(5):1780-3
pubmed: 21238784
Trends Biotechnol. 2010 Nov;28(11):580-8
pubmed: 20724010
Langmuir. 2013 Apr 16;29(15):4647-51
pubmed: 23544954
Exp Parasitol. 2016 Jul;166:150-63
pubmed: 27109311
Langmuir. 2005 Nov 8;21(23):10644-54
pubmed: 16262332
Small. 2007 Nov;3(11):1941-9
pubmed: 17963284
Infect Dis Clin North Am. 2019 Mar;33(1):79-99
pubmed: 30712769
Parasit Vectors. 2017 Jan 31;10(1):49
pubmed: 28137296
ACS Omega. 2020 Jun 24;5(26):16238-16245
pubmed: 32656446
IET Nanobiotechnol. 2018 Dec;12(8):1067-1073
pubmed: 30964015
Antimicrob Agents Chemother. 2009 Sep;53(9):3855-9
pubmed: 19546361
Iran J Pharm Res. 2019 Fall;18(4):2028-2041
pubmed: 32184867
Drug Deliv. 2018 Nov;25(1):1595-1606
pubmed: 30105918
Parasit Vectors. 2018 Apr 2;11(1):220
pubmed: 29609627
PLoS Negl Trop Dis. 2019 May 9;13(5):e0007227
pubmed: 31071090
Exp Parasitol. 2013 Sep;135(1):55-63
pubmed: 23792003
Int J Nanomedicine. 2011;6:2705-14
pubmed: 22114501
Colloids Surf B Biointerfaces. 2013 Jul 1;107:27-34
pubmed: 23466539
Int J Nanomedicine. 2017 Mar 20;12:2189-2204
pubmed: 28356736
Toxicol In Vitro. 2015 Oct;29(7):1445-53
pubmed: 26031843